Celularity (CELU) Q2 2024 earnings summary

Executive summary

• Net revenues for Q2 2024 increased 312% year-over-year to $12.1M, driven by strong Biovance 3L product sales.

• Operating loss for Q2 2024 was $10.2M, a 76% improvement from Q2 2023, reflecting higher sales and lower R&D expenses.

• The company faces substantial doubt about its ability to continue as a going concern due to liquidity constraints and upcoming debt maturities.

• No revenues from cellular therapeutics; focus remains on biomaterials and biobanking businesses.

• Ongoing efforts to secure additional capital and strategic alternatives, including asset sales or bankruptcy, if funding is not obtained.

Financial highlights

• Q2 2024 net revenues: $12.1M (Q2 2023: $2.9M); six months ended June 30, 2024: $26.8M (2023: $6.9M).

• Q2 2024 net loss: $6.5M (Q2 2023: $47.9M); six months net loss: $28.5M (2023: $112.0M).

• Gross margin improved as cost of revenues fell to 18% of sales in Q2 2024 (Q2 2023: 27%).

• R&D expenses for Q2 2024 were $3.8M, down 56% year-over-year; SG&A increased 24% to $15.9M.

• Cash and equivalents at June 30, 2024: $0.5M; total debt outstanding: $44.7M, all due within one year.

Outlook and guidance

• Company expects continued operating losses and negative cash flow for the foreseeable future.

• Additional capital is required to fund operations and repay debt; failure to secure funding may result in curtailment of operations or bankruptcy.

• No guidance provided for future revenues from cellular therapeutics; focus remains on biomaterials and biobanking.